Oscotec Inc (039200) - Total Assets
Based on the latest financial reports, Oscotec Inc (039200) holds total assets worth ₩154.14 Billion KRW (≈ $104.46 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Oscotec Inc net assets for net asset value and shareholders' equity analysis.
Oscotec Inc - Total Assets Trend (2011–2024)
This chart illustrates how Oscotec Inc's total assets have evolved over time, based on quarterly financial data.
Oscotec Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Oscotec Inc's total assets of ₩154.14 Billion consist of 82.7% current assets and 17.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 7.7% |
| Accounts Receivable | ₩34.76 Billion | 20.4% |
| Inventory | ₩1.77 Billion | 1.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩628.70 Million | 0.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Oscotec Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Oscotec Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oscotec Inc's current assets represent 82.7% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2024, up from 1.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 20.4% of total assets.
Oscotec Inc Competitors by Total Assets
Key competitors of Oscotec Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Theragen Etex Co.Ltd
KQ:066700
|
Korea | ₩245.25 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩87.88 Billion |
|
Huons Global Co. Ltd
KQ:084110
|
Korea | ₩1.47 Trillion |
|
Kolon Life Science Inc
KQ:102940
|
Korea | ₩642.14 Billion |
Oscotec Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.35 | 4.80 | 3.54 |
| Quick Ratio | 4.29 | 4.74 | 3.47 |
| Cash Ratio | 0.00 | 0.60 | 0.00 |
| Working Capital | ₩96.57 Billion | ₩112.43 Billion | ₩39.42 Billion |
Oscotec Inc - Advanced Valuation Insights
This section examines the relationship between Oscotec Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.40 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 28.8% |
| Total Assets | ₩170.78 Billion |
| Market Capitalization | $990.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oscotec Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Oscotec Inc's assets grew by 28.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oscotec Inc (2011–2024)
The table below shows the annual total assets of Oscotec Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩170.78 Billion ≈ $115.73 Million |
+28.81% |
| 2023-12-31 | ₩132.58 Billion ≈ $89.85 Million |
-7.76% |
| 2022-12-31 | ₩143.74 Billion ≈ $97.41 Million |
+193.53% |
| 2021-12-31 | ₩48.97 Billion ≈ $33.18 Million |
-35.90% |
| 2020-12-31 | ₩76.39 Billion ≈ $51.77 Million |
+5.52% |
| 2019-12-31 | ₩72.39 Billion ≈ $49.06 Million |
+3.04% |
| 2018-12-31 | ₩70.26 Billion ≈ $47.61 Million |
+73.29% |
| 2017-12-31 | ₩40.54 Billion ≈ $27.48 Million |
-0.66% |
| 2016-12-31 | ₩40.81 Billion ≈ $27.66 Million |
-17.55% |
| 2015-12-31 | ₩49.50 Billion ≈ $33.54 Million |
+36.48% |
| 2014-12-31 | ₩36.27 Billion ≈ $24.58 Million |
-3.66% |
| 2013-12-31 | ₩37.65 Billion ≈ $25.51 Million |
-12.55% |
| 2012-12-31 | ₩43.05 Billion ≈ $29.17 Million |
-10.27% |
| 2011-12-31 | ₩47.98 Billion ≈ $32.51 Million |
-- |
About Oscotec Inc
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more